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We previously reported mother-to-child transmission of HIV-1 in 9 (6.7%) of 135 children on 
nevirapine prophylaxis in Vietnam. In the current study, we investigated the appearance and 
profile of anti-retroviral drug (ARV) resistance mutations, the predicted co-receptor usage, 
and the genetic diversity of HIV-1 strains isolated from the eight pairs of HIV-1-infected 
mothers and their children, who were followed up to 12 months after birth. Portions of the pol 
and env C2V3 regions of the HIV-1 strains were analyzed genetically. HIV-1 CRF01_AE 
RNA was detected in 4 (50%) children at delivery. Y181C, a nevirapine resistance mutation, 
appeared in 2 (25%) children 1 and 3 months after birth, respectively. No ARV resistance 
mutation was detected in the mothers, though three mothers were on ARV prophylaxis. Five 
mothers and their children harbored CCR5-tropic (R5) viruses. Two mothers harbored both 
R5 and CXCR4-tropic (X4) viruses, but their children harbored only R5 viruses even though 
the X4 viruses were dominant in the mothers. In the remaining one mother, HIV-1 RNA was 
not amplified and her child harbored both R5 and X4 viruses at birth, but only X4 virus 12 
months after delivery. The infants’ viruses were more homogenous than their mothers’ (mean 
distance: 0.5% vs. 1.1%, respectively). This is the first molecular epidemiological study of 
vertical HIV-1 infections in Vietnam. These findings may provide useful knowledge for the 
prevention of mother-to-child transmission of HIV-1 and the anti-retroviral treatment of 




Vertical transmission of human immunodeficiency virus type 1 (HIV-1) accounts for the vast 
majority of pediatric AIDS cases in the world. In 2012, more than 260,000 children less than 
15 years of age were newly infected with HIV-1, more than 95% of these cases via mother-
to-child transmission (MTCT).1,2 MTCT of HIV-1 can occur in utero, intra-partum, and 
postpartum through breast feeding. Perinatally acquired infections account for the majority of 
all HIV-1 cases in children, with an estimated MTCT rate of 14 to 48% without prevention.3-6 
However, the timing and actual mechanisms of perinatal transmission are not clear. 
The chemokine receptors CCR5 and CXCR4 are the main co-receptors for HIV-1 
entry into target cells.7 Based on chemokine co-receptor usage, HIV-1 can be classified as a 
CCR5-tropic (R5), CXCR4-tropic (X4), or dual tropic (R5X4) virus.8 A strong selection for 
viral variants using CCR5 as a co-receptor occurs during transmission, as most children are 
infected with R5 viruses.9-12  
Prevention of mother-to-child transmission (PMTCT) of HIV-1 is one of the key 
components of the worldwide response to the pandemic and is based on the prophylactic use 
of anti-retroviral drugs (ARVs). In developed countries, MTCT of HIV-1 has been reduced to 
less than 2% by combination antiretroviral therapy (ART), selective caesarian delivery, and 
avoidance of breast feeding.13,14 In developing countries, single-dose nevirapine given to 
mothers infected with HIV-1 and their children in the intra-partum and immediate postnatal 
period is the most common intervention to reduce the MTCT of HIV-1. Single-dose 
nevirapine can reduce the risk of MTCT of HIV-1,15 but it may lead to the emergence of 
nevirapine-resistant HIV-1 variants in children who are infected with HIV-1 despite the 
prophylaxis.16 One study of HIV-1-infected Ugandan women and their children who received 
single-dose nevirapine to prevent MTCT showed nevirapine resistance mutations in 11 of 24 
(46%) children by 6-8 weeks of age.16 
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In Vietnam, the first pregnant woman infected with HIV-1 was reported in 1993. The 
number of HIV-1-infected pregnant women increased from 4,000 in 2007 to almost 5,000 in 
2012, and the number of children living with HIV-1 increased from 3,750 in 2007 to 5,700 in 
2012.17-19 PMTCT was officially introduced in Vietnam in 2006. According to the guidelines 
of the Vietnamese government in 2005, all HIV-1-infected pregnant women and their 
children should receive single-dose nevirapine free of charge.20 However, of the HIV-1-
infected pregnant women in Vietnam, only 9.2% in 2006, 32.3% in 2009, and 44.0% in 2011 
accessed to the PMTCT program, and 27.9% received single dose nepiravipe in 201121. Most 
of the women who had access to the PMTCT program resided in urban areas, such as Hanoi 
and Haiphong.18,21 One study reported that 7.6% of the HIV-1-infected pregnant women were 
on combination ARVs, 51.9% on single-dose nevirapine, and the remaining 40.4% without 
ARVs; only 46.2% of their children received single-dose nevirapine for PMTCT in 2008.18 
MTCT of HIV-1 was observed in 9 (6.7%) of the 135 children, who were all on 
single-dose nevirapine prophylaxis and born to mothers with and without ARV prophylaxis 
between 2004 and 2006 in Northern Vietnam.22 However, limited data is available on the 
factors associated with vertical transmission of HIV-1, such as the transmission of drug- 
resistant HIV-1 and selection based on co-receptor usage in Vietnam. 
In the present study, we investigated the appearance and profile of drug resistance-
associated mutations in infants under nevirapine prophylaxis, the predicted co-receptor usage, 








A total of 135 HIV-1-infected mothers and their children admitted to the Obstetrics and 
Gynecology hospitals in Hanoi and Haiphong, Northern Vietnam, were enrolled in our 
previous study.22 Blood samples were collected from the mothers on the day of delivery and 
from their infants within 1-2 days after birth between 2004 and 2006. Blood samples were 
also collected from the infants 1, 3, 6, and/or 12 months after birth, although some mother-
and-child pairs, especially who lived far from the hospital, could not come to the hospital at 
all the sample collection times. Plasma was separated from the blood samples within 8 hours 
of collection and stored at -80° C until analysis.  
For the current study 38 mother-and-child pairs including one with a child 
vertically infected with HIV-1 were excluded for the lack of their mothers’ plasma samples. 
Plasma samples from the remaining 97 pairs were still available and transferred to Kanazawa 
University for further analyses (Figure 1). Of the 97 children samples eight were confirmed 
to be positive for HIV-1 RNA (Table 1). Of the eight HIV-1-infected children, one (HP25) 
was born to a mother given zidovudine/lamivudine/nelfinavir 1 to 3 weeks before delivery, 
two (HN51and HN88) were born to mothers given single-dose nevirapine at delivery, and 
five (HN23, HN46, HN 47, HN60, and HP13) were born to mothers without any prophylaxis. 
After birth, all children were given single-dose nevirapine (2 mg of liquid nevirapine/kg body 
weight) within 48 hours of delivery and fed formula, and one child (HP25) whose mother 
received combination ART before delivery was given liquid zidovudine for 7 days after birth 
according to the Vietnamese national guidelines.20 All of the plasma samples collected from 
the eight HIV-1-infected children within 1-2 days after birth were available, but only a part of 
the samples collected from these children 1, 3, 6 and/or 12 months after birth were available 
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as shown in Table 1. None of the children visited any other institutes nor started ARV during 
the follow up. 
This study was approved by the ethical committees of the Hanoi National Hospital 
of Pediatrics, the National Institute of Hygiene and Epidemiology, the Obstetrics and 
Gynecology hospitals in Vietnam, and Kanazawa University in Japan. 
 
RNA extraction, RT-PCR, cloning, and sequencing 
RNA was extracted from 100 µl of plasma using the SMITEST EX-R&D nucleotide 
extraction kit (Genome Science Laboratories, Fukushima, Japan) according to the 
manufacturer’s instructions. One-step RT-PCR (SuperScript III One-step RT-PCR system 
with Platinum Taq DNA polymerase, Invitrogen, Carlsbad, CA) and nested PCR with 
AmpliTaq Gold (Applied Biosystems, Japan) or KOD FX (Toyobo, Osaka, Japan) were used 
to amplify HIV-1 pol and env. 
The HIV-1 pol-PR region (coding amino acids 1 to 99) was amplified by nested RT-
PCR with the primers DRPRO5/DRPRO2L in the first round and DRPRO1M/DRPRO6 in 
the second round. The HIV-1 pol-RT region (coding amino acids 1 to 220) was amplified 
using the primers DRRT1L/RT out in the first round and DRRT7L/DRRT6L in the second 
round. To amplify HIV-1 pol-RT, the primer pairs RT18/K104 and K101/K102 were used in 
the first and second round, respectively, when the PCR reaction with the previous primer 
pairs failed.23-25 RT-PCR was performed with one cycle at 55°C for 30 min and one cycle at 
94°C for 2 min, then 40 cycles at 94°C for 15 sec, 55°C (for DRPRO5/DRPRO2L and 
DRRT1L/RT out primer pairs) or 50°C (for the other primer sets) for 30 sec, and 68°C for 1 
min, with a final extension of 68°C for 5 min.23-25 Nested PCR for pol-PR was performed 
with one cycle at 95°C for 10 min, followed by 40 cycles at 95°C for 30 sec, 55°C for 30 sec, 
and 72°C for 1 min, with a final extension at 72°C for 10 min using Ampli Taq Gold. Nested 
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PCR for pol-RT was performed with one cycle at 94°C for 1 min and 35 cycles at 98°C for 
10 sec, 55°C for 30 sec (for DRRT7L/DRRT6L primer set) or 45°C for 30 sec (for 
KT101/K102 primer set), and 68°C for 5 min using KOD FX. 23-25 
The HIV-1 env C2V3 region (366 bases) was amplified using the primers 
JA167mod/JA170mod in the first round and JA168mod/JA169mod in the second round. 
Amplification was performed with one cycle of 95°C for 2 min and 40 cycles of 95°C for 30 
sec, 55°C for 30 sec, and 68°C for 1 min, with a final extension of 72°C for 10 min.26  
The amplified products were detected by staining the gel with ethidium bromide after 
electrophoresis. The amplified products of the PR and RT regions were sequenced directly 
with BigDye Terminator v1.1 on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). 
The amplified products of the env C2V3 region were cloned using the TOPO TA kit 
(Invitrogen) as described previously.27 Eleven to 42 clones were sequenced for each sample 
using BigDye Terminator v1.1 on a 3500XL sequencer (Applied Biosystems). 
 
Drug resistance 
HIV-1 pol PR and RT sequences were analyzed for drug resistance mutations using the 
Stanford University HIVdb sequence analysis program 
(http://hivdb.stanford.edu/pages/algs/HIVdb.html) and the International AIDS Society-USA 
March 2014 list.28,29 Drug resistance variants were defined as the presence of one or more 
major resistance-related mutations as specified by the consensus mutation figures of the 
International AIDS Society-USA29.  
 
Co-receptor usage 
HIV co-receptor usage was predicted based on the net charge of amino acids in the env V3 
region, which was calculated by subtracting the number of acidic amino acids [aspartate (D) 
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and glutamate (E)] from the number of basic amino acids [lysine (K) and arginine (R)]. A net 
charge less than +5 in the V3 region has been shown to predict CCR5 usage (R5 virus), 
whereas a net charge of more than +5 has been shown to predict CXCR4 usage (X4 virus), 
and a net charge equal to +5 indicates R5 variants unless accompanied by an arginine or 
lysine residue at position 11 or 25 of the V3 amino acid sequences.30 
 
Phylogenetic analysis 
A phylogenetic tree was constructed based on the HIV-1 env C2V3 region to elucidate the 
genetic variations between the mothers’ and their children’s viruses using ClustalW (version 
1.83) with the neighbor-joining method, and its reliability was estimated by 1,000 bootstrap 
replications. The distance of the env C2V3 region at each time point in each subject and 





HIV-1 vertical transmission and drug resistance mutations 
Of the eight HIV-1-infected children, four were positive for HIV-1 RNA at birth, and the 
remaining four were negative at birth and became positive for HIV-1 RNA 1 (HN47 and 
HN60), 3 (HN88), or 6 (HN23) months after birth (Figures 1 and 2, Tables 1 and 2). All HIV-
1 strains detected in the mothers and their infants were CRF01_AE (data not shown), 
although HIV-1 RNA was not amplified in the sample from one mother (HN46). In the HIV-
1 strains detected in the mothers, no reverse transcriptase inhibitor (RTI) or protease inhibitor 
(PI) resistance mutations were found. No ARV resistance mutations were detected in the 
children at birth, but Y181C, a non-nucleoside reverse transcriptase inhibitor (NNRTI) 
resistance mutation, appeared in two (25%) children 1 (HN51) and 3 (HP25) months after 
birth, respectively. No NRTI or PI resistance mutations were found in these children during 
the follow-up period (Table 1).  
 
Genetic diversity of HIV-1 in the mother-children pairs 
Clonal sequencing of the HIV-1 env C2V3 region was performed, and the genetic distance of 
the clones within each subject was calculated (Table 1). The mean genetic distance of the 
nucleotide sequences in the mothers ranged from 0.00 to 2.82% (median value: 1.09%) and 
from 0.06 to 2.05% (median value: 0.50%) in the children. In five pairs, the children’s 
sequences had less diversity than their mother’s sequences. In two pairs, the children’s 
sequences had higher diversity than their mother’s sequences (0.17% at birth and 0.14% 1 
month after birth vs. 0.07% in HN51, and 0.52% vs. 0.00% in HN60). Thus, the children’s 
sequences were generally more homogeneous than their mothers’ sequences. 
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 In the child HP25, the viral genetic diversity increased from 0.06% at birth to 0.89% 3 
months after birth, whereas in the child HN51 it decreased slightly from 0.17% at birth to 
0.14% 1 month after birth. 
 
Predicted HIV-1 co-receptor usage 
The multiple alignments of the amino acid sequences of the HIV-1 env V3 region and the 
predicted co-receptor usage of HIV-1 strains isolated from the eight mother-and-child pairs 
are shown in Table 2. Five mothers and their children (HN23, HN47, HN51, HN60, and 
HN88) harbored R5 viruses. Two mothers (HP13 and HP25) harbored both R5 and X4 
viruses, whereas their children harbored only R5 viruses. In the remaining one mother 
(HN46), HIV-1 RNA could not be amplified and her child harbored both R5 and X4 viruses 
at birth, but only X4 virus 12 months after delivery. 
 
Phylogenetic analysis of HIV-1 env C2V3 regions  
To examine the viral genetic relationship between each mother and her child, we performed 
phylogenetic analyses based on the HIV-1 env C2V3 nucleotide sequences (Figure 2). In five 
mother-child pairs (HN23, HN47, HN88, HP13, and HP25), the HIV-1 strains of the children 
formed more homogeneous clusters than the strains of the mothers (Figure 2A, C, and F-H), 
whereas in the HN51 and HN60 pairs the mothers’ viruses formed more homogeneous 
clusters than the children’s viruses (Figure 2D and E). In the HP25 child, the viral population 
was very homogenous at birth, but its diversity spread significantly 3 months after birth 
(Figure 2H). In the HN51 pair, the child’s viruses formed two independent clusters, at birth 
and 1 month after birth. Interestingly, the child’s virus population 1 month after birth was 
much closer to the mother’s virus population than the child’s virus population at birth (Figure 
2D). In the HP13 and HP25 pairs, the mothers’ virus populations consisted of both R5 and 
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X4 viruses, whereas their children’s consisted of only R5 viruses, even though X4 viruses 
were dominant in their mothers (Figure 2G and H). In the remaining pair, HN46, in which 
maternal HIV-1 RNA was not amplified, the child’s viruses exhibited high diversity at birth 
as well as 12 months after birth, and the virus population at birth consisted of both R5 and X4 







In the current study, we investigated the appearance and profile of ARV-resistance mutations, 
the predicted co-receptor usage, and the genetic diversity of the HIV-1 strains isolated from 
eight pairs of HIV-1-infected mothers and their children in Northern Vietnam. All of the 
children were given single-dose nevirapine at birth and followed for up to 12 months. This is 
the first molecular epidemiological study of vertical HIV-1 infection in Vietnam. 
 Of the eight HIV-1-infected children, four were positive for HIV-1 RNA at birth, 
suggesting in utero transmission of HIV-1, and four children became positive 1, 3, and 6 
months after birth, suggesting intra-partum transmission of HIV-1. All of the children were 
fed formula. Therefore, most of the children who failed PMTCT of HIV-1, even with single-
dose nevirapine within 48 hours after birth, might be infected with HIV-1 in utero and intra-
partum.  
The HIV-1 strains harboring a major nevirapine resistance mutation, Y181C, 
appeared in 2 (25%) of the 8 children 1 and 3 months after birth. This finding is consistent 
with a previous study in Ethiopia that reported a prevalence of 26% for the drug resistance 
mutation in children who received single-dose nevirapine from 2001 to 2007, and that Y181C 
was the most dominant mutation in the children.32 Other studies have reported nevirapine 
resistance mutations among 33-38% of HIV-infected children when both the children and 
their mothers were exposed to single-dose nevirapine.33-36 In the current study, the nevirapine 
resistance mutation was not detected in the children at birth, and no ARV resistance 
mutations were detected in their mothers, suggesting that the drug resistance mutation 
developed in the children independently after nevirapine administration. These findings 
completely agree with previous reports that most resistance mutations to nevirapine in 
children are selected de novo when the virus is exposed to nevirapine rather than being 
transmitted from their mothers.16 Our findings together with previous results strongly suggest 
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that longer treatment with ARV, such as 4-6 weeks of once-daily nevirapine or twice-daily 
zidovudine, which is recommended in the WHO ART guidelines 2013,37 should be 
considered as a PMTCT of HIV-1 in the children, instead of single-dose nevirapine. It is also 
suggested that ARV resistance testing is necessary for the children who failed PMTCT of 
HIV-1 before starting anti-retroviral therapy. To the best of our knowledge, this is the first 
report of the appearance and profile of ARV-resistant HIV-1 in children given single-dose 
nevirapine at birth for PMTCT in Vietnam.  
In the present study, two children (HP13 and HP25) born to mothers who had both R5 
and X4 viruses harbored only R5 viruses at birth, despite the X4 viruses being dominant in 
the mothers, demonstrating selected transmission of R5 virus from mother to child. These 
findings are consistent with previous studies in which the R5 phenotype was predominantly 
transmitted from mother to child.38,39 In contrast, one child (HN46) harbored both R5 and X4 
viruses at birth with relatively high diversity, suggesting that multiple HIV-1 strain 
transmission occurred in utero and evolved to some extent by delivery. However, whether 
HIV infection was initiated with both R5 and X4 viruses or only R5 virus(es) that evolved in 
utero to produce X4 virus populations in this child cannot be determined because no data was 
available on the mother’s virus and X4 and R5/X4 viruses can be transmitted from mother to 
child before, during, or shortly after delivery.40 
In the current study, we found that the viral populations of the children were more 
homogeneous than those of their mothers at delivery, suggesting “bottle-neck transmission” 
of HIV-1 variants from mother to child.31 However, in the two mother-child pairs, the 
children’s viral populations at birth and 1 month (HN51) and 3 months (HN60) after birth 
exhibited higher genetic diversity than their mothers’, suggesting recent infection of the 
mothers with HIV-1 and rapid viral replication and evolution in these children after birth. 
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This is in agreement with a study from Sweden in which the children’s viral populations were 
more heterogeneous than the mothers’ viral populations.31    
Phylogenetic analyses showed that single-strain infection occurred in five of the eight 
mother-child pairs, few-strain infection in two, and multiple-strain infection in one during 
vertical transmission. This finding is consistent with previous studies on MTCT of HIV-1 
showing that either single or multiple variants can be transmitted vertically,42-44 but multiple-
strain infection during vertical transmission seems to be less frequent than infection initiated 
by a single or a few closely related maternal variants.42-47 Phylogenetic analyses also showed 
relatively longer genetic distances between the viral populations of mothers and their children 
in all pairs, except for HP13, which could be due to the transmission of a minor variant from 
the mother to her child.48 
In the current study, evolution of HIV-1 strains (HP25), viral population shifts (HN46 
and HN51), and switch of co-receptor usage from R5 to X4 (HN46) were also observed in the 
children. However, the small number of HIV-1-infected mother-child pairs and incomplete 
sample collection from the children during the follow-up are acknowledged limitations in this 
study. Multicentric cohort studies are necessary to confirm these findings and to investigate 







This study was supported by the Ministry of Education in Vietnam (the 322 scholarship 
program). We are grateful to all participants enrolled in this study at Hanoi and Haiphong 
Hospitals. We thank our colleagues: Dr. Ha, Ms. Ngoc (National Institute of Hygiene and 
Epidemiology, Hanoi, Vietnam), Ms. Thuy (National Hospital of Pediatrics, Hanoi, Vietnam), 
and the members of the Viral Infection and International Health Department of the Graduate 
School of Medical Science, Kanazawa University, Japan. 
 
Sequence data 
 The sequences obtained in this study were deposited in GenBank under accession 






1. UNAIDS/WHO: Global report: UNAIDS report on the global AIDS epidemic 2012. 
UNAIDS 2012. www.unaidstoday.org. 
2. The Working Group on Mother-To-Child Transmission of HIV: Rates of mother-to-child 
transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. 
J Acquir Immune Defic Syndr 1995;8(5):506-510. 
3. European Collaborative Study: Risk factors for mother-to-child transmission of HIV-1. 
Lancet 1992;339(8800):1007-1012. 
4. Coovadian HM, Rollins NC, Bland RM et al.: Mother-to-child transmission of HIV-1 
infection during exclusive breastfeeding in the first 6 months of life: an intervention 
cohort study. Lancet 2007;369(9567):1107-1116. 
5. John GC and Kreiss J: Mother-to-child transmission of human immunodeficiency virus 
type 1. Epidemiol Rev 1996;18(2):149-157. 
6. Kourtis AP, Lee FK, Abram EJ, Jamieson DJ, and Bulterys M.: Mother to child 
transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis 
2006;6(11):726-732. 
7. Deng HK, Liu R, Ellmeier W, et al.: Identiﬁcation of a major co-receptor for primary 
isolates of HIV-1. Nature 1996;381(6584):661-666. 




9. Casper CHE, Clevestig P, Carlenor E, et al.: Link between the X4 phenotype in 
human immunodeficiency virus type 1-infected mothers and their children, despite the 
early presence of R5 in the child. J Infect Dis 2002;186(7):914-921.  
10. Nyamache AK, Muigai AW, Ng'ang'a Z, and Khamadi SA: Proﬁle of HIV type 1 
coreceptor tropism among Kenyan patients from 2009 to 2010. AIDS Res Hum 
Retroviruses 2013;29(8):1105-1109.  
11. Salvatori F and Scarlatti G: HIV type 1 chemokine receptor usage in mother-to-child 
transmission. AIDS Res Hum Retroviruses 2001;17(10):925-935.  
12. Scarlatti G, Hodara V, Rossi P, et al.: Transmission of human immunodeficiency 
virus type 1 (HIV-1) from mother to child correlates with viral phenotype. J Virol 
1993;197(2):624-629.  
13. Mofenson LM and Munderi P: Safety of antiretroviral prophylaxis of perinatal 
transmission for HIV-infected pregnant women and their infants. J Acquir Immune Deﬁc 
Syndr 2002;30(2):200-215. 
14. Newell ML and Thorne C: Antiretroviral therapy and mother-to-child transmission of 
HIV-1. Expert Rev Anti Infect Ther 2004;2(5):717-732. 
15. Jackson JB, Musoke P, Fleming T, et al.: Intrapartum and neonatal single-dose 
nevirapine compared with zidovudine for prevention of mother-to-child transmission 
of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised 
trial. The Lancet 2003;362(9387):859-868.  
18 
 
16. Eshleman SH, Mracna M, Guay LA, et al.: Selection and fading of resistance mutations 
in women and infants receiving nevirapine to prevent HIV-1 vertical transmission 
(HIVNET 012). AIDS 2001;15(15):1951-1957. 
17. UNAIDS/WHO: AIDS epidemic update. UNAIDS 2007.  
http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf.2007. 
18. Nguyen TA, Oosterhoff P, Ngoc YP, Wright P, and Hardon A: Barriers to access 
prevention of mother-to-child transmission for HIV positive women in a well-resourced 
setting in Vietnam. AIDS Res Ther 2008;5(7):01-12. 
19. Ministry of Health, Viet Nam administration of HIV/AIDS control: Viet Nam HIV/AIDS 
estimates and projections 2007-2012. Ha Noi 2009. 
20. Ministry of Health, Socialist Republic of Viet Nam. Guidelines for Diagnosis and 
Treatment of HIV/AIDS. 2005 (No. 06/2005/QĐ-BYT). 
21. Viet Nam National Committee for AIDS, Drugs and Prostitution Prevention and Control: 
Viet Nam AIDS Response Progress Report 2012. Following Up the 2011 Political 
Declaration on HIV/AIDS. Ha Noi 2012. 
http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012c
ountries/ce_VN_Narrative_Report.pdf. 
22. Ha TT, Anh NM, Bao NH, et al.: HIV-1 mother-to-child transmission, post-test 
counselling, and antiretroviral prophylaxis in Northern Viet Nam: a prospective 
observational study. Scand J Infect Dis 2012;44(11):866-873. 
19 
 
23. Lihana RW, Lwembe RM, Bi X, et al.: Efficient monitoring of HIV-1 vertically-
infected children in Kenya on first-line antiretroviral therapy. J Clin Virol 
2011;52(2):123-128. 
24. Ishizaki A, Cuong NH, Thuc PV, et al.: Proﬁle of HIV type 1 infection and genotypic 
resistance mutations antiretroviral drugs in treatment-naive HIV type 1-infected 
individuals in Hai Phong, Viet Nam. AIDS Res Hum Retroviruses 2009;25(2):175-
182. 
25. Phan TTC, Ishizaki A, Phung DC, et al.: Characterization of HIV type 1 genotypes 
and drug resistance mutations among drug-naive HIV type 1-infected patients in 
Northern Vietnam. AIDS Res Hum Retroviruses 2010;26(2):233-235. 
26. Mild M, Björndal A, Medstrand P, and Fenyö EM: Isolation of human 
immunodeficiency virus-type 1 (HIV-1) clones with biological and molecular 
properties of the primary isolate. J Virol 2006;350(1):58-66. 
27. Ndembi N, Yumo H, Takehisa J, et al.: HIV type 1 infection in Pygmy hunter gatherers 
is from contact with Bantu rather than from nonhuman primates. AIDS Res Hum 
Retroviruses 2003;19(5):435-439. 
28. HIV Drug Resistance Database, Stanford University. February 2014. 
http://hivdb.stanford.edu/pages/algs/HIVdb.html 
29. Wensing  AM, Calvez V, Gunthard HF, et al.: 2014 Update of the drug resistance 
mutations in HIV-1. Top Antivir Med 2014;22(3):642–50. 
20 
 
30. Lwembe R, Lihana RW, Ochieng W, et al.: Changes in the HIV type 1 Envelope gene 
from non-subtype B HIV type 1-infected children in Kenya. AIDS Res Hum 
Retroviruses 2009;25(2):141-147. 
31. Nowak P, Karlsson AC, Naver L, Bohlin AB, Piasek A, and Sonnerborg A: The selection 
and evolution of viral quasispecies in HIV-1 infected children. HIV Med 2002;3(1):1-11. 
32. Persaud D, Bedri A, Ziemniak C, et al.: Slower clearance of nevirapine resistant virus in 
infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV 
transmission. AIDS Res Hum Retroviruses 2011;27(8):823-829. 
33. Arrivé E, Newell ML, Ekouevi DK, et al.: Prevalence of resistance to nevirapine in 
mothers and children after single-dose exposure to prevent vertical transmission of HIV-
1: a meta-analysis. Int J Epidemiol 2007;36(5):1009-1012. 
34. Stringer JS, McConnell MS, Kiarie J, et al.: Effectiveness of non-nucleoside reverse-
transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a 
single intrapartum dose of nevirapine: a multi-country, prospective cohort study.  PLoS 
Med 2010;7(2):1-13. 
35. Moorthy A, Gupta A, Bhosala R, et al.: Nevirapine resistance and breast-milk HIV 
transmission: Effects of single and extended-dose nevirapine prophylaxis in subtype C 
HIV-infected infants. PLoS One 2009;4(1):1-8. 
36. Rotolo MW, Durand C, Cranmer L, et al.: Identification of Nevirapine-resistance HIV-1 
in the latent reservoir after single-dose Nevirapine to prevent mother-to-child 
transmission of HIV-1. J Infect Dis 2009;199(9):1301-1309. 
21 
 
37. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing 
HIV infection. June 2013  
http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf 
38. Mariangela C, Ingrid K, Marisa Z, et al.: HIV-1 with Multiple CCR5/CXCR4 Chimeric 
Receptor Use Is Predictive of Immunological Failure in Infected Children. PLoS One 
2008;3(9):1-7. 
39. Salvatori F and Scarlatti G: HIV type 1 chemokine receptor usage in mother-to-child 
transmission. AIDS Res Hum Retroviruses 2001;17(10):925-935. 
40. Huang W, Eshleman SH, Toma J, et al.: Vertical transmission of X4 tropic and dual 
tropic HIV-1 in ﬁve Ugandan mother-infant pairs. AIDS 2009;23(14):1903-1908. 
41. Wade CM, Lobidel D and Brown AJL: Analysis of human immunodeficiency virus type 
1 env and gag sequence variants derived from a mother and two vertically infected 
children provides evidence for the transmission of multiple sequence variants. J Gen 
Virol 1998;79(5):1055-1068. 
42. Wolinsky SM, Wike CM, Korber BT, et al.: Selective transmission of human 
immunodeficiency virus type-1 variants from mothers to infants. Science 
1992;255(5048):1134-1137. 
43. Dickover RE, Garratty EM, Plaeger S, and Bryson YJ: Perinatal transmission of major, 
minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and 
intrapartum. J Virol 2001;75(5):2194-2203. 
44. Scarlatti G, Leitner T, Halapi E, et al.: Comparison of variable region 3 sequences of 
human immunodeficiency virus type 1 from infected children with the RNA and DNA 
22 
 
sequences of the virus populations of their mothers. Proc Natl Acad Sci USA 
1993;90(5):1721-1725. 
45. Verhofstede C, Demecheleer E, De CN, et al.: Diversity of the human immunodeﬁciency 
virus type 1 (HIV-1) env sequence after vertical transmission in mother-child pairs 
infected with HIV-1 subtype A. J Virol 2003;77(5):3050-3057. 
46. Ahmad N, Baroudy BM, Baker RC and Chappey C: Genetic analysis of human 
immunodeficiency virus type 1 envelope V3 region isolates from mother and infants 
after perinatal transmission. J Virol 1995;69(2):1001-1012. 
47. Persaud D, Pierson T, Ruff C, et al.: A stable latent reservoir for HIV-1 in resting CD4 
(+) T lymphocytes in infected children. J Clin Invest 2000;105(7):955-1003. 
48. Ceballos A, Andreani G, Ripamonti C, et al.: Lack of viral selection in human 
immunodeficiency virus type 1 mother-to-child transmission with primary infection 





Figure 1. Mother-to-child transmission in the study group.  
AZT: zidovudine, 3TC: lamivudine, NFV: nelfinavir, NVP: nevirapine. 
#
AZT liquid was 
administered for 7 days after birth.  *All children were given single-dose liquid nevirapine 
within 48 hours of birth and fed with formula. 
 
Figure 2. Phylogenetic trees of HIV-1 env C2V3 nucleotide sequences in children and/or their 
mothers. The bootstrap values of 1000 replicates above 70% are indicated next to the node.  
   : mother’s virus, R5 variant;      : mother’s virus, X4 variant;      : child’s virus at birth, R5 
variant;       : child’s virus at birth, X4 variant;      : child’s virus 1 month after birth, R5 
variant;     : child’s virus 3 months after birth, R5 variant;      : child’s virus 6 months after 
birth, R5 variant;     : child’s virus 12 months after birth, X4 variant.  
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Table 1. Characteristics of HIV-1 strains isolated from mothers and their children in Northern 
Vietnam 
 
                
Sample ID 
 
 Drug resistance mutations Co-receptor  Distance within each subject (SE) 
NRTI NNRTI PI usage Nucleotide   Amino acid 
HN23 M None None None R5 0.25 (0.14)  
1.98 (0.46) 
 
C-0 n/a n/a n/a n/a 
    C-1 n/a n/a n/a n/a   
 C-3 n/a n/a n/a n/a    
 
C-6 n/a n/a Fail R5 0.11 (0.09)  
0.00 (0.00) 
         HN46 M n/a n/a n/a n/a 
   
 
C-0 None V106I None R5/X4 2.05 (0.52)  4.25 (1.24) 
 
C-12  None None None X4 1.10 (0.39)  
2.26 (0.91) 
         HN47 M None None None R5 1.37 (0.34)  2.57 (0.79) 
 
C-0  n/a n/a n/a n/a 
   
 
C-1  None None None R5 0.26 (0.11)  
0.62 (0.29) 
         HN51 M n/a n/a None R5 0.07 (0.04)  0.00 (0.00) 
 
C-0 None None None R5 0.17 (0.07)  
0.42 (0.20) 
 
C-1  None Y181C None R5 0.14 (0.06)  0.11 (0.09) 
         HN60 M None None None R5 0.00 (0.00)  0.00 (0.00) 
 
C-0  n/a n/a n/a n/a 
   
 
C-1  None None None n/a 
   
 
C-3  None None None R5 0.52 (0.25)  
1.35 (0.60) 
         HN88 M None None None R5 0.83 (0.28)  1.67 (0.74) 
 
C-0  n/a n/a n/a n/a 
   
 
C-3  None None None R5 0.07 (0.05)  
0.21 (0.16) 
         HP13 M None None None R5/X4 2.29 (0.78)  6.78 (1.64) 
 
C-0  None None None R5 0.11 (0.06)  
0.21 (0.14) 
         HP25 M None None None R5/X4 2.82 (0.59)    4.86 (1.17) 
 
C-0  None None None R5 0.06 (0.06)  
0.00 (0.00) 
  C-3  None Y181C None R5 0.89 (0.34)   1.39 (0.80) 
 
M, mother; C, children; C-0, at delivery; C-1, 1 month; C-3, 3 months; C-6, 6 months; C-12, 12 
months after birth; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside 
reverse transcriptase inhibitors; PI, protease inhibitor; None, no resistance mutation was detected. 
Italics, minor mutations; Bold, major mutation; R5, CCR5; X4, CXCR4; Fail, PCR (+) but 
population sequencing was not successful; n/a, no PCR amplification. Distance is expressed as 
the percent nucleotides or amino acid. 
 
Table 2. V3 amino acid sequence alignment and predicted co-receptor usage of HIV-1 strains isolated from 
mothers and their children in Northern Vietnam 
                                        V3 amino acid sequence Number of Net 11/25 Predicted
11 25 clones (Total) charge amino acid phenotype
Consensus C T R P S N N T R T S I T I G P G Q V - F Y R TG D I I G D I R K A YC
HN23
       M . . . . . . . . . . . V P . . . . . . - . . . . . . . T . . . . . . . .          31 (42) 3 S/D R5
. . . . . . . . . . . V P . . . . . . - . . . . . . . T . H . . . . . . 9 4 S/D R5
. A . . . . . . . . . V P . . . . . . - . . . . . . . T . H . . . . . .    1  4 S/D R5
. . . . . . . . . . . V P . . . . . . - . . T . . . . T . . . . . . . . 1 2 S/D R5
          C-6 . . . . . . . . . . . . N . . . . . . - . . . . . . . . . . . . . . . .          16 (16) 3 S/D R5
HN46
          C-0 . . . . - Y D . K . K V . R . . . K . - Y . . . . E . T . . . . . . . .         2 (13) 5 K/E  X4*
. . . . - Y . . . . K A . R . . . K . - Y . . . . E . T . . . . . . . . 2 6 K/E X4
. . . . - Y E . K . K V . R . . . K . - Y . . . . E . T . . . . . . . . 1 5 K/E  X4*
. . . . - Y D . G . K V . R . . . K . - Y . . . . E . R . . . . . . . . 1 5 K/E  X4*
. . . . - Y E . G . K A . R . . . K . - Y . . . . E . T . . . . . . . . 1 4 K/E R5
. . . . - Y . . K . Q V . R . . . K . - Y . . . . E . T . . . . . . . . 2 5 Q/E R5
. . . . - Y E . E . K V . R . . . K . - Y . . . . E . T . . . . . . . . 1 3 K/E R5
. . . . - Y E . K . K A . R . . . K . - Y . T . . E . T . . . . . . . . 1 4 K/E R5
. . . . - Y E . Q . K A . R . . . K . - Y . . . . E . T . . . . . . . . 1 4 K/E R5
. . . . - Y . . K . Q V . R . . . K . - Y . T . . E . T . . . . . . . . 1 4 Q/E R5
          C-12 . . . . - Y . . N . K A . R . . . K . - Y . . . . E . T . . . . . . . .         5 (15) 5 K/E  X4*
. . . . - Y . . E . K A . R . . . K . - Y . . . . K . T . . . . . . . . 1 6 K/K X4
. . . . - Y K . E . K A . R . . . K . - Y . . . . K . T . . . . . . . . 3 7 K/K X4
. . . . - Y . . N . K A . R . . . K . - Y . . . . K . T . . . . . . . . 3 7 K/K X4
. . . . - Y K . E . K A . R . . . K . - Y . . . . E . T . . . . . . . . 2 5 K/E  X4*
. . . . - Y K A E . K A . R . . . K . - Y . . . . K . T . . . . . . . . 1 7 K/K X4
HN47
     M . . . . . . . . . . . M . . . . . . . - . . . . . G . . . . . . . . . .          7  (15) 4 S/G R5
. I . . . . . . . . . M . . . . . . . - . . . . . G . . . . . . . . . . 7 4 S/G R5
. . . . . . . . . . . M . . . . . . I - . . . . . . . . . . . . . . . . 1 3 S/D R5
         C-1 . . . . . . . . . . . M . . . . . . . - . . . . . G . . . . . . . . . .         8 (11) 4 S/G R5
. . . . . . . . . . . MN . . . . . . - . . . . . G . . . . . . . . . . 1 4 S/G R5
. . . . F . . . . . . M . . . . . . . - . . . . . G . . . . . . . . . . 1 4 S/G R5
. . . . . . . . . . . M . . . . . . . - . D . . . G . . . . . . . . . . 1 3 S/G R5
HN51
      M . . . . . . . . . . . V A . . . . . . - . . . . . . . . . . . . . . . .           16 (16) 3 S/D R5
         C-0 . . . . . . . . . . . L . . . . . . . - . . . . . . . . . . . . . . . .           16 (16) 3 S/D R5
         C-1 . . . . . . . . . . . V A . . . . . . - . . . . . . . . . . . . . . . .           16 (16) 3 S/D R5
HN60
      M . . . . . . . . . K . T . . . . . . . L . . . . . . . . . . . K . . . .           14 (14) 4 S/D R5
         C-3 . . . . . . . . . K . T . . . . . . . L . . . . . N V . . . . . . . F .         7 (15) 5 S/N R5
. . . . . . . . . K . T . . . . . . . L . . . . . . . . . . . . . . F . 7 4 S/D R5
. . . . . . . . . K . T . . . . . . . L . . . A . . . . . . . . . . F . 1 4 S/D R5
HN88
    M . . . . . . . . . K G . . . . . . . . - . . . . . E . . . . . . . . . .          13 (14) 4 G/E R5
. . . . . . . . . K G V . . . . . . . - . . . . . E . . . . . . . . . . 1 4 G/E R5
       C-3 . . . . . . . . . K G . . . . . . . . - . . . . . E . . . . . . . . . .           16 (16) 4 G/E R5
HP13
     M . . . . . . . I . . R M . . . . . K . - . . . . . E . . . . . . . . . .         6 (16) 5 R/E  X4*
. . . . Y . . I . . R M . . . . . K . - . . . . . E . . . . . . . . . . 2 5 R/E  X4*
. . . . . . . . . . G . . . . . . . . - . . . . . E . . . . . . . . . . 6 3 G/E R5
. . . . . . . I . . G . . . . . . . . - . . . . . E . . . . . . . . . . 1 3 G/E R5
. . . . . . . . I . . L . . . . . . . - . . . . . . . K . . . . . . . . 1 3 S/D R5
        C-0 . . . . . . . . . . G . . . . . . . . - . . . . . E . . . . . . . . . .           16 (16) 3 G/E R5
HP25
     M . . . . . . . . . . K V . M . . . R . - . . . . . E . . R . . . . . . .            20 (34) 6 K/E X4
. . . . . . . . . . . . N . . . . R . - . . . . . E . . . . . . . . . . 1 5 K/E  X4*
. . . . . . . . . . K V . M . . . R . - . . . . . E . . . . . . . . . . 1 5 K/E  X4*
. . T . . . . . . . K V . M . . . R . - . . . . . E . . R . . . . . . .   10 4 S/E R5
. . . . . . . . . . . . N . . . . R . - . . . . . E . . R . . . . . . . 2 5 S/E R5
        C-0 . . . . . . . . . . . . . M . . . . . - . . . . . . . M . . . . . . . .           16 (16) 3 S/D R5
        C-3 . . . . . . . . . . G . . M . . . . . - . . . . . . . . . . . . . . . .         6 (16) 3 G/D R5
. . . . . . . . . S . . . M . . . . . - . . . . . . . . . . . . . . . .  5 3 S/D R5
. . . . . . . . . . G . . M . . . . . - . . . . . . . . . . . K . . . . 3 3 G/D R5
. . . . . . . . . S . . . M . . . . . - . . . . . . . . . . . K . . . . 2 3 S/D R5
Sample ID
A net charge of less than and more than +5 in the V3 region indicated CCR5-using (R5) and CXCR4-using 
(X4) variants, respectively, and a net charge of +5 indicated R5 variants * unless accompanied by an arginine 
(R) or lysine (K) residue at position 11 or 25 of the V3 amino acid sequence. 
